person · Reporting owner
Elliott Jeffrey Thomas
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXACT SCIENCES CORPEXAS · Entity 56619 | Chief Financial Officer | April 30, 2024 | May 02, 2024 |
| EXAGEN INC.XGN · Entity 935 | Director | June 18, 2020 | July 02, 2020 |
| ICON PLCICLR · Entity 3439 | Director | August 10, 2026 | August 11, 2026 |
| Quanterix CorpQTRX · Entity 6649 | Director | August 19, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXACT SCIENCES CORP
Report date April 30, 2024 · Filed May 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,795 |
Last balance in matching sequence
After 2024-05-01 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2024-04-30 · Grant · Acquired 291 · Balance 11,224 F1: Represents additional shares of common stock received upon settlement of a performance share unit award on April 30, 2024. F2: In addition to the shares of Common Stock reported on this Form 4, which total 13,380 shares, Mr. Elliott also holds, in the aggregate, an additional 134,437 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Row 2 · 2024-04-30 · Grant · Acquired 707 · Balance 11,931 F3: Represents shares of common stock purchased through Employee Stock Purchase Plan. F2: In addition to the shares of Common Stock reported on this Form 4, which total 13,380 shares, Mr. Elliott also holds, in the aggregate, an additional 134,437 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Row 3 · 2024-05-01 · Sale · Disposed 136 · Balance 11,795 F4: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain performance stock units. F2: In addition to the shares of Common Stock reported on this Form 4, which total 13,380 shares, Mr. Elliott also holds, in the aggregate, an additional 134,437 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectHeld in 401(k) Plan | 1,585 |
Reported balance
Holding disclosure · report date 2024-04-30 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,585 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents additional shares of common stock received upon settlement of a performance share unit award on April 30, 2024.
F2: In addition to the shares of Common Stock reported on this Form 4, which total 13,380 shares, Mr. Elliott also holds, in the aggregate, an additional 134,437 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.
F3: Represents shares of common stock purchased through Employee Stock Purchase Plan.
F4: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain performance stock units.
EXAGEN INC.
Report date June 18, 2020 · Filed July 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.00 · Expires 2030-06-17 | Direct | 9,000 |
Reported balance
After 2020-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-18 · Grant · Acquired 9,000 · Balance 9,000 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
ICON PLC
Report date August 10, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 1,324 |
Reported balance
After 2026-08-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-10 · Grant · Acquired 1,324 · Balance 1,324 F1: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. F2: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting.
F2: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027.
Quanterix Corp
Report date August 19, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,345 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Exercise / conversion · Acquired 3,955 · Balance 15,345 F1: Restricted stock units convert into common stock on a one-for-one basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 4,075 |
Reported balance
After 2026-08-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-19 · Exercise / conversion · Disposed 3,955 · Balance 4,075 F2: On August 19, 2024, the reporting person was granted 11,985 restricted stock units, vesting 33%, 33%, and 34% on the first, second, and third anniversaries of the grant date, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: On August 19, 2024, the reporting person was granted 11,985 restricted stock units, vesting 33%, 33%, and 34% on the first, second, and third anniversaries of the grant date, respectively.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SERA PROGNOSTICS, INC.
Report date June 04, 2026 · Filed June 04, 2026
Section 16 reporting ended · disclosed 2026-06-04. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2017 Filed Feb 13, 2018 16:14 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 679 | $13.26 | $9,003.54 |
DisclosureSEC source: 0001209191-18-009525 · doc5.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,694 F1 · shares: Represents shares purchased through Employee Stock Purchase Plan. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 16:18 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 5,846 | $39.41 | $230,390.86 |
DisclosureSEC source: 0001209191-17-046912 · doc4.xml · nonDerivative · entry 2 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,015 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on July 28, 2017. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 16:18 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-046912 · doc4.xml · derivative · entry 4 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award granted on July 28, 2016 that partially vested on July 28, 2017. The restricted stock units vest in four equal annual installments beginning on July 28, 2017. F4 · derivative.expiration_date: Represents a restricted stock unit award granted on July 28, 2016 that partially vested on July 28, 2017. The restricted stock units vest in four equal annual installments beginning on July 28, 2017. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 16:18 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-046912 · doc4.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| July 27, 2017 Filed Jul 28, 2017 16:17 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantRestricted Stock Units · Derivative | 37,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-046574 · doc4.xml · derivative · entry 4 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,200 Underlying: Common Stock · 37,200 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · date: This restricted stock unit award was granted by the Compensation Committee of the Company's Board of Directors on February 23, 2017, contingent upon stockholder approval of the Plan Amendment. The Company's stockholders approved the Plan Amendment at the Company's 2017 Annual Meeting of Stockholders on July 27, 2017. F6 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on February 23, 2018. F6 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on February 23, 2018. Read SEC document |
| July 27, 2017 Filed Jul 28, 2017 16:17 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $21.68 | $0.00 |
DisclosureSEC source: 0001209191-17-046574 · doc4.xml · derivative · entry 3 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-02-23 F2 · date: This option award was granted by the Compensation Committee of the Board of Directors of Exact Sciences Corporation (the "Company") on February 23, 2017, contingent upon stockholder approval of Amendment No. 1 to the Company's 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective April 28, 2015) (the "Plan Amendment"). The Company's stockholders approved the Plan Amendment at the Company's 2017 Annual Meeting of Stockholders on July 27, 2017. F3 · derivative.exercise_date: These options vest and become exercisable in four equal annual installments beginning on February 23, 2018. Read SEC document |
| May 01, 2017 Filed Jul 28, 2017 16:17 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 1,111 | $13.26 | $14,731.86 |
DisclosureSEC source: 0001209191-17-046574 · doc4.xml · nonDerivative · entry 1 Elliott Jeffrey Thomas · CIK 0001689757 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,111 F1 · shares: Represents shares of common stock purchased through Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.